drugset / Trial / NCT03698513

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513

Phase 1 Completed 113 enrolled Bristol-Myers Squibb
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will investigate the safety and interaction of BMS-986177 in healthy volunteers, when administered with Aspirin and/or Clopidogrel

Timeline

Start
2018-10-04
Primary completion
2019-02-19
Completion
2019-02-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 325 mg
Subject Clopidogrel Small molecule 75 mg
Subject Milvexian Small molecule 200 mg Oral

Indications

No indication recorded.